Short Interest in Sanofi (NASDAQ:SNY) Increases By 67.9%

Sanofi (NASDAQ:SNY - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 5,440,000 shares, a growth of 67.9% from the April 15th total of 3,240,000 shares. Based on an average daily volume of 2,030,000 shares, the short-interest ratio is currently 2.7 days. Approximately 0.2% of the company's stock are short sold.

Hedge Funds Weigh In On Sanofi

A number of hedge funds have recently added to or reduced their stakes in SNY. Cardinal Capital Management grew its holdings in Sanofi by 0.3% during the fourth quarter. Cardinal Capital Management now owns 58,854 shares of the company's stock valued at $2,927,000 after purchasing an additional 201 shares during the last quarter. TCTC Holdings LLC grew its holdings in Sanofi by 28.0% during the first quarter. TCTC Holdings LLC now owns 960 shares of the company's stock valued at $47,000 after purchasing an additional 210 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in shares of Sanofi by 3.4% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company's stock worth $325,000 after acquiring an additional 216 shares during the last quarter. Wynn Capital LLC grew its stake in shares of Sanofi by 4.5% in the first quarter. Wynn Capital LLC now owns 5,266 shares of the company's stock worth $256,000 after acquiring an additional 226 shares during the last quarter. Finally, Angeles Investment Advisors LLC grew its stake in shares of Sanofi by 2.1% in the fourth quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company's stock worth $598,000 after acquiring an additional 244 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company's stock.

Sanofi Stock Up 1.2 %

Shares of NASDAQ SNY traded up $0.59 during mid-day trading on Friday, reaching $49.28. The company had a trading volume of 1,062,734 shares, compared to its average volume of 2,556,279. The stock has a fifty day moving average of $48.04 and a two-hundred day moving average of $48.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The company has a market capitalization of $124.66 billion, a price-to-earnings ratio of 24.76, a PEG ratio of 1.36 and a beta of 0.61. Sanofi has a 12-month low of $42.63 and a 12-month high of $55.72.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a $1.478 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. This is an increase from Sanofi's previous annual dividend of $1.38. Sanofi's dividend payout ratio is currently 73.87%.

Analyst Ratings Changes

SNY has been the topic of a number of research reports. Morgan Stanley initiated coverage on shares of Sanofi in a report on Tuesday, January 23rd. They set an "equal weight" rating and a $55.00 target price on the stock. TheStreet cut shares of Sanofi from a "b" rating to a "c" rating in a report on Friday, February 9th. Finally, StockNews.com lowered shares of Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.